Tema Oncology ETF Rating $25.81 -0.40 (-1.53%) Closing price 07/11/2025 03:52 PM EasternExtended Trading$25.75 -0.06 (-0.23%) As of 07/11/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Tema Oncology ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy 2.81Holdings in CANC have an aggregate rating of Moderate Buy based on 572 analyst ratings issued in the past year covering 45 companies (87.5% of the portfolio).CANC Aggregate Price Target$25.81High Prediction$25.81Average Prediction$25.81Low Prediction$25.81Holdings in CANC have an aggregate price target of $25.81 and a range of $25.81 to $25.81 covering 45 companies (87.5% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy19 Buy rating(s)Moderate Buy20 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 45 CANC Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.26%RHHBYRoche$40.49-1.8%N/A2.5775.12%LLYEli Lilly and Company$793.34+0.3%4.982 of 5 stars2.75$1,012.56 27.6%20Trending NewsAnalyst ForecastAnalyst Revision4.81%RVMDRevolution Medicines$38.02-1.2%4.5764 of 5 stars3.00$68.00 78.9%114.57%BBIOBridgeBio Pharma$46.47+0.4%4.5848 of 5 stars3.00$60.21 29.6%14Analyst Upgrade4.05%EXELExelixis$44.86-0.7%4.7906 of 5 stars2.48$44.72 -0.3%21Analyst Forecast3.75%MRUSMerus$54.50-1.1%1.892 of 5 stars3.14$84.64 55.3%14News CoverageAnalyst UpgradeInsider Trade3.65%GMABGenmab A/S$21.40-2.1%4.1076 of 5 stars2.67$37.80 76.6%12Positive NewsAnalyst Forecast3.52%BMYBristol Myers Squibb$46.91-3.3%4.8975 of 5 stars2.32$57.69 23.0%22Trending NewsAnalyst ForecastAnalyst Revision3.51%NUVLNuvalent$80.93-1.4%3.3079 of 5 stars3.17$119.60 47.8%12Insider Trade3.45%AMGNAmgen$295.27-1.7%4.4389 of 5 stars2.35$307.82 4.2%23Positive NewsAnalyst Revision3.32%SMMTSummit Therapeutics$25.00-3.4%2.8298 of 5 stars2.79$34.67 38.7%143.09%ACLXArcellx$68.98+0.2%2.5591 of 5 stars3.07$111.23 61.3%15Positive News2.87%ZLABZai Lab$32.73-4.0%3.0694 of 5 stars2.80$54.28 65.8%5Gap Up2.80%LEGNLegend Biotech$38.96-1.9%3.3981 of 5 stars2.91$72.70 86.6%11Analyst Forecast2.60%MRKMerck & Co., Inc.$83.35-0.8%4.994 of 5 stars2.43$108.69 30.4%21Trending NewsAnalyst ForecastAnalyst Revision2.59%ONCBeOne Medicines$250.30-1.2%3.4523 of 5 stars3.00$320.67 28.1%6Trending NewsAnalyst DowngradeInsider Trade2.10%IDYAIDEAYA Biosciences$22.48-1.4%3.6232 of 5 stars2.85$47.55 111.5%13News CoverageAnalyst Upgrade1.88%ABBVAbbVie$192.32-1.4%4.4982 of 5 stars2.81$211.29 9.9%27Trending NewsAnalyst Revision1.69%CGONCG Oncology$26.72-1.4%2.4267 of 5 stars3.08$56.80 112.6%12Positive NewsAnalyst Upgrade1.65%JANXJanux Therapeutics$25.15-1.8%1.9645 of 5 stars3.08$91.89 265.4%12News CoverageAnalyst Forecast1.41%REGNRegeneron Pharmaceuticals$567.74+1.4%4.8347 of 5 stars2.80$814.57 43.5%25Trending NewsAnalyst ForecastAnalyst Revision1.40%GILDGilead Sciences$109.64-4.3%4.9357 of 5 stars2.77$111.38 1.6%26Positive NewsAnalyst Revision1.39%ARGXargenex$560.24-0.5%4.4032 of 5 stars3.10$728.06 30.0%21Analyst Upgrade1.39%NRIXNurix Therapeutics$12.44-1.8%1.5984 of 5 stars2.83$29.59 137.8%18Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap Down1.37%IMNMImmunome$8.64-3.5%2.1002 of 5 stars3.00$23.33 170.1%6Positive News1.20%COGTCogent Biosciences$10.98+1.2%3.0485 of 5 stars2.82$18.00 63.9%11Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading Volume1.07%SNDXSyndax Pharmaceuticals$9.59-2.3%3.0332 of 5 stars2.90$34.30 257.7%10Analyst Forecast1.00%DAWNDay One Biopharmaceuticals$6.79-5.6%2.5157 of 5 stars3.14$29.00 327.1%7News Coverage1.00%IMCRImmunocore$35.02-1.2%1.4695 of 5 stars2.55$58.89 68.2%11News Coverage0.92%ZYMEZymeworks$13.34-2.3%2.913 of 5 stars2.90$21.00 57.4%100.92%ELVNEnliven Therapeutics$22.45-1.4%2.8331 of 5 stars3.00$41.20 83.5%5Insider Trade0.92%HCMHUTCHMED$16.04+0.4%1.63 of 5 stars2.00$19.00 18.5%2Gap Down0.85%AAPGAscentage Pharma Group International$38.24-6.1%N/A3.001News CoverageGap Down0.78%GHGuardant Health$50.25-2.0%4.089 of 5 stars3.00$53.76 7.0%210.76%ARVNArvinas$7.79-1.3%3.94 of 5 stars2.55$20.29 160.5%220.70%RCUSArcus Biosciences$9.35-2.0%2.1514 of 5 stars2.89$21.29 127.7%9News Coverage0.67%ILMNIllumina$99.25-0.8%4.8743 of 5 stars2.40$125.11 26.1%20Trending NewsAnalyst Forecast0.54%REPLReplimune Group$10.97+1.9%4.0824 of 5 stars3.13$20.83 89.9%8News CoverageHigh Trading Volume0.50%SDGRSchrodinger$21.01-3.2%2.5138 of 5 stars2.75$33.25 58.3%4Positive News0.48%RLAYRelay Therapeutics$3.60-3.5%2.1735 of 5 stars2.83$17.67 390.7%12News CoveragePositive NewsInsider Trade0.45%CGEMCullinan Therapeutics$7.70-1.8%1.7348 of 5 stars3.00$30.00 289.6%5News Coverage0.39%NUVBNuvation Bio$2.20-4.8%3.266 of 5 stars3.20$7.17 225.8%50.39%AUTLAutolus Therapeutics$2.47-0.4%2.877 of 5 stars3.00$9.32 277.3%50.37%ANABAnaptysBio$26.20+0.4%1.7492 of 5 stars2.80$42.38 61.7%10Positive News0.30%CELCCelcuity$13.63+0.1%2.2861 of 5 stars3.17$28.40 108.4%6Positive News This page (NASDAQ:CANC) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CANC Stock Alerts